SEC Tracker
Get the app

10x Genomics TXG

10x Genomics Q1 FY24: revenue $141.0M; diluted EPS −$0.50

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers 10x Genomics reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$141.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$59.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.50No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$355.8MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$15.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when 10x Genomics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3826 and related industry codes: the same peer list as the financial tables.

  1. Cohu COHU public float $879M, Jun 27, 2025
  2. Aehr Test Systems AEHR public float $671M, Nov 28, 2025
  3. Transcat TRNS public float $670M, Sep 27, 2025
  4. EyePoint EYPT public float $643M, Jun 30, 2025
  5. Onto Innovation ONTO

Data on this page was fetched . The filing on SEC.gov is the record.